Please login to the form below

Not currently logged in
Email:
Password:

etanercept

This page shows the latest etanercept news and features for those working in and with pharma, biotech and healthcare.

Amgen strikes $240m autoimmune deal with Evoq Therapeutics

Amgen strikes $240m autoimmune deal with Evoq Therapeutics

Otezla fits right into Amgen’s existing psoriasis and anti-inflammatory product range, which includes Enbrel (etanercept) and Amgevita, its biosimilar of AbbVie’s Humira (adalimumab) which is approved and already

Latest news

More from news
Approximately 7 fully matching, plus 93 partially matching documents found.

Latest Intelligence

  • Will biosimilars ever catch on in the US? Will biosimilars ever catch on in the US?

    The UK has been especially proactive with biosimilars. Three biologics there – infliximab, rituximab and etanercept –underwent an average price reduction of 40% when their biosimilars were introduced.

  • The tipping point The tipping point

    Driving disparity. If we look across Europe at biosimilar penetration, even the recently launched infliximab and etanercept biosimilars show highly variable uptake between markets.

  • Deal Watch October 2016 Deal Watch October 2016

    For example Samsung Bioepis also based in South Korea, signed a deal with Merck &Co in 2013 for a range of biosimilars including infliximab, trastuzumab and etanercept (Amgen's Enbrel with ... The FDA accepted the Biologics Licence Application for

  • Cost containment and the German market Cost containment and the German market

    The main sales drivers are biopharmaceutical medicines like the monoclonal antibody adalimumab, TNF-alpha inhibitor etanercept as well as the oncologic drugs imatinib and enzalutamide.

  • Biosimilars - the same, but different? Biosimilars - the same, but different?

    drugs Humira (adalimumab) and Enbrel (etanercept) - last year's first and third best selling drugs respectively - are also in the biosimilar firing line.

More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Covid-19: how is it affecting prescribing patterns?

    From March 2019, use of on-patent Etanercept, Adalimumab and Rituximab went down, while the Adalimumab biosimilar went up and so did Etanercept and Rituximab biosimilars.  This is to be expected

  • The Biosimilar Challenge

    These include the infliximab biosimilars Inflectra and Remsima, the etanercept biosimilar Benepali (launched last year) and biosimilars to adalimumab, filgrastim and bevacizumab preparing to launch on the horizon. .

  • Infographic: RA Perceptions

    expect current market leaders Enbrel (etanercept) and Humira (adalimumab) to continue to lead the market and be used to treat over a third of Rheumatoid Arthritis (RA) patients in three years’

  • Brand leaders in RA will lose market share, predict rheumatologists

    leaders Enbrel (etanercept) and Humira (adalimumab) will continue to lose market share to newer biologics such as RoActemra (tocilizumab), Orencia (abatacept) and Simponi (golimumab) and may experience strong competition from biosimilar

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Spirit

We find the soul in the science, the humanity in the data, harnessing the power of creativity to deliver medical...

Latest intelligence

01 PME-APR21 Cover.jpg
Virtual congresses: video thrilled the cardio tsar
Chris Ross explores the key learnings from a year of virtual congresses...
When Will We Be Back To Normal?
The definitive question of 2021, whether you’re a homeschooling parent, a homebound professional, a wanderer with nowhere to go… or all three at once....
How to tell your healthcare story.
Healthcare research is not a simple story and the people in charge of those moments need to be careful about the story that they tell....

Infographics